Literature DB >> 22783418

Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma.

Sakura Izumiya1, Mitsuaki Ishida, Keiko Hodohara, Takashi Yoshida, Hidetoshi Okabe.   

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmacytic proliferations that develop as a consequence of immunosuppression in a recipient of a solid organ, bone marrow or stem cell allograft. The development of PTLDs is usually associated with Epstein-Barr virus (EBV) and the disorder is also termed EBV-associated lymphoproliferative disorder (LPD). The development of PTLD is a rare complication in autologous bone marrow/peripheral blood stem cell transplantation. In the present study, we report a case of EBV-associated LPD which developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma. A 51-year-old male presented with swelling of the left cervical lymph nodes. A biopsy revealed nodular sclerosis classical Hodgkin's lymphoma. Following four courses of ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) therapy, the Hodgkin's lymphoma relapsed. CHASE (cyclophosphamide, etoposide, cytarabine, dexamethasone) therapy and autologous peripheral blood stem cell transplantation were performed. In the 128 days following the transplantation, lymph node swelling was noted and a biopsy specimen demonstrated EBV-associated LPD. The serum copy number of EBV-DNA was 2.7×10(3) copies/ml. The occurrence of EBV-associated LPD may be on the rise due to the increased number of patients undergoing immunosuppression therapy. The measurement of the serum EBV-DNA copy number and the detection of EBV-infected atypical lymphocytes using in situ hybridization are significant in establishing an early accurate diagnosis and initiating the correct treatment for EBV-associated LPD in patients with immunosuppression.

Entities:  

Year:  2012        PMID: 22783418      PMCID: PMC3392596          DOI: 10.3892/ol.2012.670

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

Review 1.  Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus.

Authors:  A F List; F A Greco; L B Vogler
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma.

Authors:  Motoki Ohta; Takashi Taga; Akitaka Nomura; Hirofumi Kato; Tomoyuki Takano; Yoshihiro Maruo; Yoshihiro Takeuchi; Mitsuaki Ishida; Shigeru Ohta
Journal:  J Med Virol       Date:  2011-09       Impact factor: 2.327

Review 3.  Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.

Authors:  M A Lones; I Kirov; J W Said; I P Shintaku; S Neudorf
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

4.  Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.

Authors:  S Caillard; C Lelong; F Pessione; B Moulin
Journal:  Am J Transplant       Date:  2006-11       Impact factor: 8.086

5.  Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.

Authors:  John A Heath; Emmett H Broxson; Mukund G Dole; Daniel A Filippa; Diane George; David Lyden; Ira J Dunkel
Journal:  J Pediatr Hematol Oncol       Date:  2002-02       Impact factor: 1.289

6.  Early onset post-transplant lymphoproliferative disease is associated with allograft localization.

Authors:  Nicolaas A Bakker; Gustaaf W van Imhoff; Erik A M Verschuuren; Willem J van Son; Jaap J Homan van der Heide; Nic J G M Veeger; Philip M Kluin; Hanneke C Kluin-Nelemans
Journal:  Clin Transplant       Date:  2005-06       Impact factor: 2.863

7.  A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation.

Authors:  A J Peniket; A R Perry; C D Williams; A MacMillan; M J Watts; P G Isaacson; A H Goldstone; D C Linch
Journal:  Bone Marrow Transplant       Date:  1998-08       Impact factor: 5.483

8.  Lymphomas after solid organ transplantation: a collaborative transplant study report.

Authors:  Gerhard Opelz; Bernd Döhler
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

9.  Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Authors:  Richard A Nash; Roger Dansey; Jan Storek; George E Georges; James D Bowen; Leona A Holmberg; George H Kraft; Maureen D Mayes; Kevin T McDonagh; Chien-Shing Chen; John Dipersio; C Fred Lemaistre; Steven Pavletic; Keith M Sullivan; Julie Sunderhaus; Daniel E Furst; Peter A McSweeney
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

Review 10.  Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.

Authors:  Ellen Meijer; Jan J Cornelissen
Journal:  Curr Opin Hematol       Date:  2008-11       Impact factor: 3.284

View more
  2 in total

1.  Immune reconstitution after allogeneic hematopoietic stem cell transplantation in children: a single institution study of 59 patients.

Authors:  Hyun O Kim; Hyun Jin Oh; Jae Wook Lee; Pil-Sang Jang; Nack-Gyun Chung; Bin Cho; Hack-Ki Kim
Journal:  Korean J Pediatr       Date:  2013-01-29

2.  Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis.

Authors:  Mitsuaki Ishida; Keiko Hodohara; Miyuki Yoshii; Hiroko Okuno; Akiko Horinouchi; Ryota Nakanishi; Ayumi Harada; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Takashi Yoshida; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.